BEIJING, Sept. 25 (Xinhua) -- Two inactivated COVID-19 vaccines developed by the China National Biotec Group (CNBG) are under phase-3 clinical trials in the Middle East, with more than 35,000 people inoculated, according to an official with the Ministry of Science and Technology (MOST).
Wu Yuanbin, director-general of science and technology for social development with the MOST, said during a press conference in Beijing on Friday that Chinese vaccine production enterprises signed cooperative agreements with institutions from a number of countries to jointly implement phase-3 clinical trials in accordance with the laws and regulations.
The trials in the Middle East have so far shown good safety and no serious adverse reactions, Wu said.
Up till now, there have been 11 Chinese COVID-19 vaccines entering clinical trials, with four in phase-3 clinical trials.
Did you find this article insightful?
100% readers found this article insightful